Enovis CORP (ENOV): what the price assumes

boothcheck covers Enovis CORP (ENOV) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed 2026-07-25.

Generated: 2026-09-07 · Exported: 2026-09-09 · Source: https://boothcheck.com/report/ENOV

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 10: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

The price sits below what even a 5%/yr operating-profit decline would warrant; the inversion reports a bound, not a solved growth path.

Solve inputs: computed at a 7% cost of capital with 4% terminal growth over a 5-year stage (computed at the 7% minimum rate; the CAPM rate 6.6% sits below it).

How unusual the bet is: n/a

Valuation X-Ray

The price is supported by asset-based value. A value/asset-supported name, not a pure growth bet.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Asset

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 4.4%); the inversion above states its own rate.

Per-Model Detail (n=3)

Economic-Unit Decomposition (Sum Of The Parts)

One or more material disclosed units has unresolved economics. Unknown/general is not evidence of homogeneity: segment SOTP is primary but incomplete, consolidated cash flow may remain only a secondary cross-check when every unit shares an enterprise basis, and one sector multiple or target margin is withheld.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Leverage and coverage are computed on normalized mid-cycle operating income (mid-cycle margin 6.9%); the trailing year was depressed.

Bullet Takeaways

• Two businesses of roughly equal size sit inside Enovis: a bracing and recovery franchise the 10-K describes as operating where "The markets in which our Prevention & Recovery segment competes are highly competitive and fragmented.", and a surgical implant business assembled largely by acquisition.
• The accounting has already conceded what those acquisitions cost, with goodwill write-offs of $1,049.8 million recorded during 2025 on top of $645.0 million the year before.
• The nearer question is whether the implant side keeps outrunning the rest: it grew 6% organically in the first quarter of 2026 while the bracing side was roughly flat, against a full-year plan that needs 4% to 6% organic growth from both.

Bull Case

Two businesses of similar size sit under one roof here, and they do not earn their money the same way. Prevention & Recovery sells bracing, cold therapy, bone growth stimulators and pain management devices into a market the 10-K describes without flattery: "The markets in which our Prevention & Recovery segment competes are highly competitive and fragmented." Fragmented is the operative word. Nobody owns that market, which caps the pricing power but also means demand does not turn on a handful of hospital contracts. Reconstructive is the opposite shape. Surgical implants are a scale business, where the barrier is the cost of putting instrument sets in operating rooms and keeping a direct sales force beside surgeons, and where a sub-scale player carries the same fixed cost as a large one across fewer procedures.

The margin data across the peer set says exactly where that scale threshold sits. SYK earns roughly a 19.7% operating margin on $25.27 billion of trailing revenue. ZBH earns about 14.0% on $8.41 billion. GMED, a third of Zimmer's size, still manages 17.2% on $3.10 billion while growing 23.5%. Below the threshold the picture inverts: ATEC, at $787 million of revenue, runs an operating margin of about -7.7%. Enovis sits between those poles, with a through-the-cycle operating margin near 6.9%. The bull case is that gap. Every point of margin between where this company operates and where scaled implant makers operate is worth roughly a fifth of the current market value, and closing even part of it requires no new market and no new product category, only volume moving across a cost base that is already built.

There are signs the volume is moving. First-quarter 2026 sales reached $589 million, up 5% as reported and 3% organically, with the implant side growing 11% reported and 6% organic while the bracing side held flat. Adjusted EBITDA, the company's own non-GAAP measure, came in at $104 million, or 17.6% of sales in the quarter. And the spending is aimed at the part of the business where scale is actually won, which the 10-K states directly: "Research and development costs also increased compared to the prior year period, primarily due to increased spend within recently acquired businesses in our Recon segment, which is investing in surgical productivity solutions and computer-assisted surgery technologies." Surgical productivity is not a marketing word in this industry. It is how an implant company earns the right to a surgeon's next hundred cases.

None of this requires heroic assumptions to matter, which is the unusual part. Today's price embeds a through-the-cycle operating profit that shrinks slightly, about 0.8% a year, for the next five years. The bull does not need margin convergence with Stryker. It needs the operating profit line to stop going backwards. The balance sheet is the reason the market is willing to demand so little, and that is a fair objection rather than a footnote. But a company whose price assumes decline, in a market where the scaled operators earn mid-teens margins, is being asked to clear a bar it has already cleared in better quarters.

Bear Case

An implant business sold through a direct sales force is a fixed-cost business, and the 10-K is unusually plain about what that means when procedure volumes turn: "Additionally, these fixed costs may slow our ability to reduce costs in the face of a sudden decline in demand for such products, which could have a material adverse impact on our results of operations." Orthopedic demand is not volatile in the way semiconductor demand is, but it is not immune either, and the operating leverage that makes the bull case attractive on the way up works identically in reverse. This is a company that needs volume growth to hold in order for its cost base to make sense.

That much is cyclical. What has already happened is not. During 2025 the company recorded goodwill write-offs totaling $1,049.8 million, following $645.0 million the year before, against a market value now near $1.5 billion. Those were not one judgment repeated. An interim test on October 3, 2025 produced a charge of $540.8 million, and a second test produced a further $501.0 million, split $157.6 million against Prevention & Recovery and $343.4 million against Reconstructive. Both reporting units failed, twice, in a single year. The acquisitions that built the implant segment were paid for at prices the company's own valuation work now says were too high, and the auditors have signed that conclusion.

What the acquisitions borrowed did not get written down alongside the goodwill. Long-term borrowings stood at 1,261.8 million dollars at the end of 2025. They sit under a credit agreement amended on December 8, 2025 that carries a $700 million term loan and a $1.1 billion revolver, with quarterly principal repayments of 8.75 million dollars running to a December 2030 maturity. Net borrowings work out to roughly 8.3 times operating profit on a through-the-cycle basis, a level that leaves little room between a soft year and a covenant conversation. Liquidity at the corporate level is thin. Readily available assets amount to 33.1 million dollars. The 10-K names the consequence: "This additional financing may not be available or, if available, may not be on terms acceptable to us."

Here is the part that makes the low priced-in bar less comforting than it first reads. The price already assumes through-the-cycle operating profit shrinks slightly for five years, so a bear cannot simply argue the market is too optimistic about growth. The bear argument is aimed one level down, at the through-the-cycle number itself. That figure, a 6.9% operating margin, is a normalization of what the business has earned across better and worse years. On a trailing basis the operating line runs about -27% of sales. If the normalized figure is itself flattered by years that included the acquired revenue at its acquisition-case margins, then the anchor under the whole frame moves, and a valuation that looked undemanding at 17 times a normalized profit looks quite different against a smaller one.

The floor under all of this is real but modest. The company holds roughly 251 million dollars of equity stakes outside its operating business, a bit under a sixth of today's market value, and that is a genuine boundary on the downside rather than a rounding item. Book value per share, at $25.77 against a $27.02 price, looks like a second floor, and it is worth being careful there: over a billion dollars of that book was erased in a single year, which is a demonstration that the number moves. Meanwhile the share count keeps drifting up, compounding near 1.6% a year over the last four years, and shareholders approved another 3,650,000 shares for the equity incentive plan in May 2026. That is a small leak, but it runs in one direction.

Valuation

At $27.02, the market is not asking this company for much. The price works out to roughly 17 times a through-the-cycle operating profit, and it embeds that profit shrinking by about 0.8% a year over a five-year stage. Put plainly: the price assumes the business gets slightly smaller. That is an unusual thing for a medical technology company to be assigned, and it is the single most important fact about how this stock is priced.

The normalization matters more than usual here, so it is worth being explicit about which number is in use. On a trailing twelve-month basis the operating line runs about -27% of sales, wrecked by the goodwill charges taken during 2025. The through-the-cycle figure, roughly a 6.9% operating margin, is what the priced-in arithmetic runs on. One more caution about precision: each percentage point of cost of capital swings the implied growth rate by roughly 7 points, which means the answer here is far more sensitive to the discount rate than to any operating assumption. Treat the negative growth requirement as a direction, not a measurement.

The methods behave the way they must when trailing earnings are negative. Earnings-power and forward-growth lenses have nothing usable to work with, so what supports the price is the balance sheet. Book value per share sits at $25.77, and the asset-value methods land within a few percent of the current price on either side. That is the whole support structure: this is a value read resting on the carrying value of the assets, not an earnings read and not a growth read. The comparison to peers sharpens it rather than softening it, because ZBH runs a 14.0% operating margin and GMED 17.2%, and Enovis is priced as though it will never get anywhere near either.

Which returns the weight to the balance sheet, where the tension in this stock actually lives. Net borrowings sit near 8.3 times operating profit on a through-the-cycle basis, and readily available assets at the corporate level amount to 33.1 million dollars. The term loan amortizes steadily into a December 2030 maturity, which is a schedule that does not renegotiate itself. Roughly 251 million dollars of equity stakes held outside the operating business sit behind the common as a separate boundary. Between a book value that has proven it can be revised by a billion dollars in a year and a debt schedule that cannot, the asset support beneath this price is real but not fixed, and that distinction is the one a buyer at $27.02 is actually taking a view on.

Catalysts

First-quarter results, reported May 7, 2026 for the quarter ended April 3, 2026, were the cleanest read on the operating trend in a year cluttered by write-offs. Net sales came to $589 million, up 5% as reported and 3% organically, with Reconstructive growing 11% reported and 6% organic and Prevention & Recovery flat on a reported basis and up 1% organically. Adjusted EBITDA, the company's own non-GAAP measure, was $104 million, or 17.6% of sales, and the reported bottom line was close to breakeven. Management attributed part of the softness in the quarter to fewer selling days.

The full-year plan was left unchanged alongside those results. Enovis reaffirmed 2026 revenue of approximately $2.31 billion to $2.37 billion, incorporating 4% to 6% organic growth, with full-year 2026 adjusted EBITDA of $425 million to $435 million and free cash flow conversion expected at 25% or higher. Because the first quarter delivered 3% organic growth against a 4% to 6% annual target, the second half carries the arithmetic, which makes the next two reports the ones that settle whether the guidance holds.

Two structural items sit alongside the operating story. In December 2025 the company amended its credit agreement into a $700 million term loan and a $1.1 billion revolving facility, both maturing in December 2030, using part of the new term borrowing to repay about $335 million then drawn on the revolver. That pushed the refinancing question out several years. Then in May 2026 shareholders approved an additional 3,650,000 shares for the equity incentive plan, an amendment the board had adopted on March 31, 2026. Neither is dramatic on its own. Together they describe a company that has bought itself time and is paying for talent in equity while it uses that time.

Peer Cohorts (Per Segment, With Filing Citations)

Prevention & Recovery (P&R) (reported)

• ZBH (ZIMMER BIOMET HOLDINGS, INC.)
• FY2025 10-K: …charges. "Buy local" initiatives have in the past resulted in, and could in the future result in, reduced demand for our products, as well as reduced margins on covered devices and products, required renegotiation of distributor arrangements and incurrence of inventory-related charges. Similarly, the Italian Public…
• FY2025 10-K: …while continuing to satisfy the demand for our products; product liability, intellectual property and commercial litigation losses; and the ability to obtain and maintain adequate intellectual property protection. See also the section titled "Risk Factors" (refer to Part I, Item 1A of this report) for further…
• SYK (STRYKER CORP)
• FY2025 10-K: …and reimbursement levels from third- party payors; • changes in the competitive environment; • breaches, failures or other disruptions of our or our vendors' or customers' information technology systems or products, including by cyber-attack, data leakage, unauthorized access or theft; • a significant increase in…
• FY2025 10-K: …technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Our products include surgical equipment and surgical navigation systems; endoscopic and…
• SNN (Smith & Nephew plc)
• FY2025 20-F: …returns are estimated based on historical sales and returns information. These estimates are reviewed regularly and adjusted as necessary. The Group maintains an estimated refund liability based upon the expected value method that is recorded as a reduction in revenue. Rebates primarily comprise chargebacks and other…
• FY2025 20-F: …Other information continued Reported revenue growth, the most directly comparable financial measure calculated in accordance with IFRS, reconciles to underlying revenue growth as follows: Reconciling items 2025 Reported growth Underlying growth Acquisitions/ disposals Currency impact Consolidated revenue by business…
• GMED (GLOBUS MEDICAL, INC.)
• FY2025 10-K: …under development or impact our ability to modify our currently approved or cleared products on a timely basis. Any delay in, or failure to receive or maintain, clearance or approval for our products under development could prevent us from generating revenue from these products or achieving profitability. Conducting…
• FY2025 10-K: …macroeconomic pressures or uncertainty associated with local or global economic recessions, disruption associated with pandemics, or other customer-specific factors. 77 Table of Conten t s GLOBUS MEDICAL, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued) (v) Income Taxes Deferred tax assets…
• ATEC (Alphatec Holdings, Inc.)
• FY2025 10-K: …reflect the Company's future ability to collect outstanding receivables or if the financial condition of customers were to deteriorate, resulting in impairment of their ability to make payments, an increase in the provision for doubtful accounts may be required. F- 12 Table of Contents The Company's accounts…
• FY2025 10-K: …whenever events or changes in circumstances indicate that the carrying value may not be recoverable. Factors that could trigger an impairment review include significant under-performance relative to expected historical or projected future operating results, significant changes in the manner of our use of the acquired…
• STE (STERIS plc)
• FY2025 10-K: …Business Conduct, as well as the Charters of the Audit Committee, the Compensation and Organization Development Committee, the Nominating and Governance Committee, and the Compliance and Technology Committee of the Company's Board of Directors. CORPORATE RESPONSIBILITY Introduction WE HELP OUR CUSTOMERS CREATE A…
• FY2025 10-K: …statements. Refer to Note 13 titled, "Business Segment Information" for disaggregation of revenue. Product Revenues Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer's purchase order and may include a distributor, dealer…
• ICUI (ICU MEDICAL INC/DE)
• FY2025 10-K: …in our revenue. Research and Development We continue to invest in certain research and development ("R&D") projects to drive future growth and to remain competitive in our product lines. Our main R&D facilities are located in the U.S and India. Our R&D costs primarily relate to headcount and employment expense in…
• FY2025 10-K: …on both a fixed and tiered/variable basis. In both cases, we use information available at the time, including current contractual requirements, our historical experience with each customer and forecasted customer purchasing patterns, to estimate the most likely rebate amount. We also warrant products against defects…
• BAX (BAXTER INTERNATIONAL INC)
• FY2025 10-K: …or services, could cause us to lose market share and could significantly adversely affect our business. Furthermore, product development requires substantial investment and there is inherent risk in the R&D process. A successful product development process further depends on many other factors, including our ability…
• FY2025 10-K: …to technology or products under development acquired in a business combination which have not received regulatory approval and have no alternative future use. Acquired IPR&D is capitalized as an indefinite-lived intangible asset. Development costs incurred after the acquisition are expensed as incurred. Upon receipt…

Reconstructive (Recon) (reported)

• ZBH (ZIMMER BIOMET HOLDINGS, INC.)
• FY2025 10-K: …by borrowing on our committed revolving credit facilities. For additional information on our debt, including types of debt, maturity dates, interest rates, debt covenants and available revolving credit facilities, see Note 12 to our consolidated financial statements. In February, May, August and December 2025, our…
• FY2025 10-K: …present significant operational, legal, financial and cultural challenges and risks that are similar to those found in our above-described U.S. sales force transformation efforts, which risks may be magnified by the complexity of implementing different changes across multiple markets in parallel. The change in…
• SYK (STRYKER CORP)
• FY2025 10-K: …investments of deferred employee compensation. Accounts Receivable: Accounts receivable include trade and other miscellaneous receivables. An allowance is maintained for doubtful accounts for estimated losses in the collection of accounts receivable. Estimates are made regarding the ability of customers to make…
• FY2025 10-K: …technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Our products include surgical equipment and surgical navigation systems; endoscopic and…
• SNN (Smith & Nephew plc)
• FY2025 20-F: …Other information continued Reported revenue growth, the most directly comparable financial measure calculated in accordance with IFRS, reconciles to underlying revenue growth as follows: Reconciling items 2025 Reported growth Underlying growth Acquisitions/ disposals Currency impact Consolidated revenue by business…
• FY2025 20-F: Implant, the guidance supports the notion that bioinductive implants can reduce the risk of re-tears21 and offer better patient outcomes.21 The HEALICOIL◊ family of shoulder anchors features an open architecture designed to facilitate healing and is available in our REGENESORB◊ material, which can be shown to be…
• GMED (GLOBUS MEDICAL, INC.)
• FY2025 10-K: …used in an expansive range of spine, orthopedic trauma, hip, knee and extremity procedures. The majority of our Musculoskeletal Solutions contracts have a single performance obligation and revenue is recognized at a point in time. For our IONM services, revenue is recognized in the period the service is performed for…
• FY2025 10-K: …and performance restricted stock units ("PRSUs"), as part of the NuVasive Merger. These RSUs and PRSUs are measured at the grant date based on the estimated fair value of the award. The fair value of equity instruments that are expected to vest is recognized and amortized over the requisite service period. The…
• ATEC (Alphatec Holdings, Inc.)
• FY2025 10-K: …reflect the Company's future ability to collect outstanding receivables or if the financial condition of customers were to deteriorate, resulting in impairment of their ability to make payments, an increase in the provision for doubtful accounts may be required. F- 12 Table of Contents The Company's accounts…
• FY2025 10-K: …systems to increase the surface area for cell adhesion and proliferation. Spinal alignment can be further achieved with our lordotic expandable intervertebral body fusion systems. We also offer several standalone implants designed to provide for height restoration and stabilization in one integrated solution.…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.